Evidence map›Paper›PMID 36747229›Full record

ArticleMalaria journal2023

Effect of large-scale mass drug administration for malaria on mortality and morbidity in Angumu health zone, Ituri, Democratic Republic of Congo.

Lise Grout, Yves Katuala Givo, Trish Newport, Tom Adoum Mahamat, Priscillah Gitahi, Jean Jacques Mandagot, Michel Quere, Sophie Wodon, Iza Ciglenecki, Mathieu Bastard and 5 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Lise GroutEpicentre, Geneva, Switzerland. lise.grout@epicentre.msf.org.
Yves Katuala GivoMédecins Sans Frontières, Goma, Democratic Republic of Congo.
Trish NewportMédecins Sans Frontières, Geneva, Switzerland.
Tom Adoum MahamatMédecins Sans Frontières, Goma, Democratic Republic of Congo.
Priscillah GitahiMédecins Sans Frontières, Goma, Democratic Republic of Congo.
Jean Jacques MandagotMédecins Sans Frontières, Goma, Democratic Republic of Congo.
Michel QuereMédecins Sans Frontières, Geneva, Switzerland.
Sophie WodonMédecins Sans Frontières, Geneva, Switzerland.
Iza CigleneckiMédecins Sans Frontières, Geneva, Switzerland.
Mathieu BastardEpicentre, Geneva, Switzerland.
Francis BaelongandiMinistry of Health, Bunia, Democratic Republic of Congo.
Louis TshuloMinistry of Health, Bunia, Democratic Republic of Congo.
Herman Jakisa UlubaMinistry of Health, Bunia, Democratic Republic of Congo.
Esther SterkMédecins Sans Frontières, Geneva, Switzerland.
Etienne GignouxEpicentre, Geneva, Switzerland.
Médecins Sans Frontières · CHUniversity of Goma · CDMinistry of Public Health · CDEpicentre (South Africa) · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngumu health zone in Ituri, Democratic Republic of Congo, is a highly malaria-endemic area with an overburdened health system and hosting internally displaced persons (IDP). The World Health Organization recommends mass drug administration (MDA) for malaria in complex emergencies. Therefore, three MDA rounds were implemented by Ministry of Public Health and Médecins sans Frontières from September 2020 to January 2021 in four health areas selected for epidemiological (high malaria incidence) and logistic reasons. Reported mortality and morbidity were compared in locations where MDA has been performed and locations where it has not.

methodsA non-randomized controlled population-based retrospective mortality survey was conducted in March 2021. Two-stage cluster sampling was used in villages; all IDP sites were surveyed with systematic random sampling. The main (mortality rates) and secondary (morbidity) outcomes were estimated and compared between locations where MDA had been conducted and where it had not, using mixed Poisson and binomial regression models respectively.

resultsData was collected for 2554 households and 15470 individuals, of whom 721 died in the 18-month recall period. The under-five mortality rate (U5MR) decreased in the locations where MDA had been implemented from 2.32 [1.48-3.16] "before" the MDA to 1.10 [0.5-1.71] deaths/10,000 children under 5 years/day "after", whereas it remained stable from 2.74 [2.08-3.40] to 2.67 [1.84-3.50] deaths/10,000 children/day in the same time periods in locations where MDA had not been implemented. The U5MR and malaria-specific mortality was significantly higher in non-MDA locations after MDA was implemented (aRR = 2.17 [1.36-3.49] and 2.60 [1.56-4.33], respectively, for all-cause and malaria-specific mortality among children  < 5 years). Morbidity (all age and  < 5 years, all cause or malaria-specific) appeared lower in MDA locations 2.5 months after last round: reported malaria-specific morbidity was 14.7% [11-18] and 25.0% [19-31] in villages and IDP sites where MDA had been implemented, while it was 30.4% [27-33] and 49.3% [45-54] in villages and IDP sites with no MDA.

conclusionsDespite traditional limitations associated with non-randomized controlled retrospective surveys, the documented sharp decrease of under-5 mortality and morbidity shows that MDA has the potential to become an important malaria-control tool in emergency settings. Based on these results, new MDA rounds, along with indoor residual spraying campaigns, have been planned in the health zone in 2022. A set of surveys will be conducted before, during and after these rounds to confirm the effect observed in 2021 and assess its duration.

Indexed as

MalariaMass Drug AdministrationChildChild, PreschoolDemocratic Republic of the CongoHumansIncidenceRetrospective StudiesSurveys and QuestionnairesDemocratic Republic of CongoMalariaMass drug administration (MDA)MortalityPrevention

Identifiers

PMID36747229
PMCPMC9901819
OpenAlexW4319315040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.